How Merck’s Recent Performance Frames the Valuation Story

With Merck’s share price hovering just above the 100 dollar mark, many investors are wondering whether they are looking at a solid long term compounder or a stock that has already priced in most of its upside. The recent performance numbers offer a useful starting point for framing that valuation debate.

Over the last week, Merck has inched up around 0.8%, adding to a stronger 6.4% gain over the past month and a more modest 1.9% return year to date. Stretch that lens out further, and the stock’s 7.0% return over the last year and 55.0% gain over five years highlight a business that has rewarded patient shareholders, even if the 3 year return of around minus 1.0% shows that…